GC Pharma getting closer to world’s first commercialized recombinant protein for hepatitis B
GC Pharma(CEO Eun-Cheol Huh), formally known as Green Cross, announced on the 18th that the Phase II/III clinical trial plan for ‘GC1102(Hepabig-gene),’ a recombinant immunoglobulin for the treatment of hepatitis B, has acquired approval from the Ministry of Food and Drug Safety.
The hepatitis B...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
